[1. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 2016;6:194.10.3389/fcimb.2016.00194]Search in Google Scholar
[2. Zhang L-J, Gallo RL. Antimicrobial peptides. Curr Biol. 2016 Jan 11;26(1):R14-9.10.1016/j.cub.2015.11.017]Search in Google Scholar
[3. Bahar A, Ren D, Bahar AA, Ren D. Antimicrobial Peptides. Pharmaceuticals. 2013 Nov 28;6(12):1543–75.10.3390/ph6121543]Search in Google Scholar
[4. Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov. 2012;11:37–51.10.1038/nrd3591]Search in Google Scholar
[5. Lakshmaiah Narayana J, Chen JY. Antimicrobial peptides: Possible anti-infective agents. Peptides. 2015;72:88–94.10.1016/j.peptides.2015.05.012]Search in Google Scholar
[6. Li Y, Xiang Q, Zhang Q, Huang Y, Su Z. Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides. 2012;37:207–15.10.1016/j.peptides.2012.07.001]Search in Google Scholar
[7. Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–7.10.1038/nbt1267]Search in Google Scholar
[8. Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat. 2016;26(6):689–702.10.1080/13543776.2016.1176149]Search in Google Scholar
[9. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol. 2013;31(5):379–82.10.1038/nbt.2572]Search in Google Scholar
[10. Park CB, Kim MS, Kim SC. A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem Biophys Res Commun. 1996;218:408–13.10.1006/bbrc.1996.0071]Search in Google Scholar
[11. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998;244:253–7.10.1006/bbrc.1998.8159]Search in Google Scholar
[12. Uyterhoeven ET, Butler CH, Ko D, Elmore DE. Investigating the nucleic acid interactions and antimicrobial mechanism of buforin II. FEBS Lett. 2008;582:1715–8.10.1016/j.febslet.2008.04.036]Search in Google Scholar
[13. Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 2008;271:47–55.10.1016/j.canlet.2008.05.041]Search in Google Scholar
[14. Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24:21.10.1186/s12929-017-0328-x]Search in Google Scholar
[15. Salamon P, Miklóssy I, Albert B, Korodi M, Nagy K, Bakos I, et al. Heterologous Expression and Purification of Recombinant Proapoptotic Human Protein Smac/Diablo with EGFP as Fusion Partner. Stud Univ Babeș-Bolyai Chem. 2017 Jun;62(2):333–45.10.24193/subbchem.2017.2.26]Search in Google Scholar
[16. Boda FA, Salamon P, Orbán C, Berta L, Curticăpean A, Gâz Șerban A, et al. Heterologous expression and purification of recombinant crotoxin B, the phospholipase A2 subunit of crotoxin. Stud Univ Babes-Bolyai Chem. 2018;10.24193/subbchem.2018.1.01]Search in Google Scholar
[17. Wang Q, Zhu F, Xin Y, Liu J, Luo L, Yin Z. Expression and purification of antimicrobial peptide buforin IIb in Escherichia coli. Biotechnol Lett. 2011;33:2121–6.10.1007/s10529-011-0687-4]Search in Google Scholar